Diazyme is introducing a new High Sensitivity Troponin I (hs-cTnI) assay that is run on a fully automated Chemiluminescence Immunoassay (CLIA) analyzer, Maglumi 2000 plus (DZ-Lite 3000). The assay is for research use only in U.S.

Studies indicate that due to its high tissue specificity, cardiac Troponin I (cTnI) is a specific and sensitive marker for the detection of myocardial damage.¹

Studies report that high sensitive troponin I (hs-cTnI) assay improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.²

A recent clinical study suggested that cTnI assessed by a high-sensitivity assay is prognostic beyond traditional cardiovascular risk factors for HF and mortality in the general HF-free community. The prognostic utility of hs-cTnI goes beyond that of NT-proBNP, and the data suggest that these 2 assays are complementary in identification of at-risk individuals in the general community.³
hs-cTnI ASSAY

ASSAY SPECIFICATIONS

**Method:**
Immunoluminescent (CLIA)

**Sample:**
Serum

**LOQ:**
~3.2 pg/mL (CV<20%)

**LOD:**
~1.0 pg/mL

**Dynamic Range:**
Up to 2000 pg/mL cTnl

**Throughput:**
90 tests/hour

**99% Value:**
7.0 pg/mL

**CV% at 99% Value:**
<8%

**Traceable to NIST SRM 2921**

PRECISION

<table>
<thead>
<tr>
<th></th>
<th>Sample 1</th>
<th>Sample 2</th>
<th>Sample 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average (pg/mL)</td>
<td>2.14</td>
<td>7.53</td>
<td>14.99</td>
</tr>
<tr>
<td>SD (pg/mL)</td>
<td>0.17</td>
<td>0.35</td>
<td>0.20</td>
</tr>
<tr>
<td>CV%</td>
<td>7.74%</td>
<td>4.71%</td>
<td>1.36%</td>
</tr>
</tbody>
</table>

DISTRIBUTION

![Graph showing frequency distribution of hs-cTnI](image)

